Cotellic
Named-patient access overview. Cotellic is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Cotellic (cobimetinib) is an oral selective MEK1/MEK2 inhibitor developed by Genentech (a member of the Roche Group). The US Food and Drug Administration approved Cotellic in November 2015 for use in combination with vemurafenib (Zelboraf) for the treatment of adult patients with unresectable or metastatic melanoma harbouring a BRAF V600E or V600K mutation. Cotellic is given as a 60 mg once-daily oral tablet on a 21-days-on, 7-days-off schedule within each 28-day cycle, alongside continuous vemurafenib dosing. Treatment is supervised by a medical oncologist experienced in BRAF and MEK inhibitor combination therapy.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Cotellic
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Cotellic is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country access guide for Cotellic in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Cotellic
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.